Welcome to our dedicated page for Mesa Laboratories SEC filings (Ticker: MLAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Mesa Laboratories, Inc. (MLAB) SEC filings page on Stock Titan provides access to the company’s regulatory documents as filed with the U.S. Securities and Exchange Commission. Mesa is a Colorado corporation whose common stock is listed on The Nasdaq Stock Market LLC under the symbol MLAB, and it regularly submits reports and disclosures that detail its operations, governance, and financial condition.
Through this page, users can review current and historical filings such as Form 8-K reports, which Mesa uses to announce material events. Recent 8-K filings have covered topics including quarterly financial results, the creation of direct financial obligations under its credit facility, and the settlement of outstanding convertible notes. These filings often reference accompanying press releases that provide additional narrative and financial tables.
Investors can also find proxy materials, such as the company’s definitive proxy statement (DEF 14A). This document outlines items for shareholder vote at the annual meeting, including the election of directors, ratification of the independent registered public accounting firm, advisory votes on executive compensation, and amendments to equity incentive plans. The proxy statement also describes Mesa’s board committees and aspects of its executive compensation framework.
In addition to these documents, Mesa’s SEC filings reference its credit facility, leverage metrics, and other capital structure details, giving readers insight into how the company finances its operations and manages debt. Stock Titan’s interface surfaces these filings with AI-powered summaries that help explain key sections, making it easier to understand complex disclosures without reading every page.
Users interested in MLAB can use this page to monitor new filings as they are posted to EDGAR, review past disclosures, and better understand the regulatory and governance context surrounding Mesa’s life science tools and quality control business.
Mesa Laboratories delivered modest top-line growth with stronger profits for the nine months ended December 31, 2025. Revenue rose to $185.4 million from $178.8 million, while net income more than doubled to $10.8 million, lifting diluted EPS to $1.95 from $0.94.
Growth came mainly from Sterilization and Disinfection Control, Biopharmaceutical Development, and Calibration Solutions, while Clinical Genomics declined due to weaker demand in China. Gross margin stayed solid at 62.6%, and operating income improved to $15.8 million.
The company refinanced its 1.375% convertible notes, settling the $97.5 million principal at maturity using its credit facility, which now includes a $68.4 million term loan and $98.3 million drawn on the revolver. Cash was $29.0 million, with operating cash flow of $28.9 million and continued quarterly dividends of $0.16 per share. Management highlights ongoing macro headwinds in China and notes that the Clinical Genomics unit remains more sensitive to potential future goodwill impairment.
Mesa Laboratories, Inc. filed a current report to let investors know it has released financial results. On February 3, 2026, the company issued a press release covering its performance for the three and nine months ended December 31, 2025.
The press release is included as Exhibit 99.1 and is provided as supplemental information. The company specifies that this earnings information is being furnished, not filed, which means it is not subject to certain liability provisions of the securities laws or automatically incorporated into other securities offerings.
Mesa Laboratories Inc. director reports a gift of company stock. A Form 4 filing shows that on 12/02/2025, the reporting director disposed of 2,000 shares of Mesa Laboratories common stock in a transaction coded "G," which indicates a gift, at a reported price of $0.
Following this transaction, the director beneficially owns 25,282 shares directly and 44,780 shares indirectly through a spousal lifetime access trust. The filing notes that the indirectly held shares are owned by a trust for a spouse’s benefit, which the director reports as indirect beneficial ownership.
Mesa Laboratories (MLAB) reported Q2 FY2026 results with revenues of $60.7 million, up 5% year over year, and gross profit of $37.3 million (61.5% margin). Operating income rose to $4.7 million, while net income was $2.5 million and diluted EPS was $0.45, reflecting higher interest and lower non‑operating gains versus last year.
Growth was led by Biopharmaceutical Development (revenue $13.9 million, +17.3%) and Calibration Solutions (revenue $13.6 million, +10.7%). Sterilization and Disinfection Control was flat, and Clinical Genomics declined modestly as China revenue fell to $5.3 million from $7.4 million. For the first half, revenue reached $120.3 million (+3.7%) and diluted EPS was $1.30.
The company retired its 1.375% convertible notes at maturity on August 15, 2025 using its revolver and cash; no notes remain outstanding. The revolver balance was $106.0 million at quarter‑end, and an October amendment lowered the spread, reducing the borrowing rate from 7.1% to 6.7%. Cash was $20.4 million. Mesa initiated cost actions expected to reduce annualized costs by about $3.2 million, with $0.9 million to be reinvested, implying $2.3 million net savings starting in Q3; approximately $0.85 million in severance was incurred.
Mesa Laboratories (MLAB) announced it issued a press release covering results for the three and six months ended September 30, 2025. The company furnished the press release as Exhibit 99.1 to this Form 8‑K.
The information provided with the press release is being furnished, not filed, which means it is not subject to Section 18 liabilities and is not incorporated by reference into Securities Act filings. The filing lists MLAB common stock on The Nasdaq Stock Market LLC.
Mesa Laboratories (MLAB) reported an insider equity change: the President and CEO acquired 11,558 shares of common stock on 10/27/2025 via a transaction coded M, reflecting settlement of performance share units at a reported price of $0.
Following this transaction, the officer directly holds 64,135 shares. The shares relate to performance share units granted on 10/28/2021 as a special award intended to encourage continued performance and long-term retention, vesting one-third on 10/27/2024 and on each of the next two anniversary dates.
BlackRock, Inc. reports beneficial ownership of 378,897 shares of Mesa Laboratories, Inc. (MLAB), representing 6.9% of the outstanding common stock. The filing (Schedule 13G, Amendment No. 10) shows BlackRock has sole voting power for 373,374 shares and sole dispositive power for 378,897 shares. The form states these holdings are held in the ordinary course of business and not for the purpose of changing or influencing control. The issuer's principal executive office is listed at 12100 W 6th Ave, Lakewood, CO. The document includes a certification signed by Spencer Fleming, Managing Director, dated 10/02/2025.
Mesa Laboratories, Inc. held its annual meeting on August 22, 2025. Holders of 5,501,454 shares were entitled to vote and 5,203,377 shares were represented in person or by proxy. Seven director nominees — John J. Sullivan, Gary M. Owens, Jennifer S. Alltoft, Shannon M. Hall, Shiraz S. Ladiwala, R. Tony Tripeny and Mark C. Capone — were each elected to one-year terms through the 2026 annual meeting. The board then appointed committee members. Shareholders ratified Baker Tilly US, LLP as the independent registered public accounting firm for the fiscal year ending March 31, 2026. On a non-binding advisory basis, shareholders approved the compensation of the company’s named executive officers as disclosed in the proxy statement.
Shiraz Ladiwala, a director of Mesa Laboratories, received restricted stock unit vestings and holds common stock. On August 15, 2025, 1,949 RSUs vested and were reported as acquired resulting in 1,949 shares delivered at $0 per share. Additionally, 3,810 RSUs granted on the same date were reported as unvested and remain scheduled to vest on August 15, 2026, representing an additional 3,810 shares. After the vested delivery, the reporting person beneficially owned 5,023 shares of Mesa Laboratories common stock. The Form 4 was filed by one reporting person and lists the reporting person as a director. The filing was signed under power of attorney on August 15, 2025.
John James Sullivan, a director of Mesa Laboratories, reported transactions dated 08/15/2025 related to his company equity awards and holdings. The filing shows 1,404 restricted stock units (RSUs) vested and were converted into 1,404 shares with a reported price of $0, increasing his direct common stock holdings to 27,282 shares. The report also records an additional grant of 2,784 RSUs that vest on 08/15/2026 and are reported as 2,784 shares of direct beneficial ownership once settled. Separately, 44,780 shares are held indirectly via a spousal lifetime access trust. All transactions were reported on Form 4 and appear to be routine equity compensation activity by an insider.